A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Phase 2 Completed 40 enrolled Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. Shanghai 6th People's Hospital · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

A study on the safety, efficacy, pharmacokinetics and pharmacodynamics of Supaglutide dosing weekly and bi-weekly in patients with type 2 diabetes mellitus.

Timeline

Start: 2020-04-14
Primary completion: 2020-10-25
Completion: 2021-03-16

Publications

Lou YR, Xu YL, Xiong Y, Deng C, Wang Q. Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes. Clin Pharmacokinet. 2025 Apr;64(4):533-552. doi: 10.1007/s40262-025-01475-7. Epub 2025 Feb 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Supaglutide	Unknown	—	Subcutaneous

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Summary

Timeline

Publications

Drugs

Indications